The theme: Commercial biotechs earning real money alongside clinical-stage names whose value rests entirely on a pipeline. The score gap between the two is wide and deliberate — a pre-revenue company is graded on what it has, not on what it might become.
No other theme scores lower on the median name than this one does at 24.5, which is worth sitting with before reading the ranking as a buy list.
Strongest to weakest, these names sit further apart than in any other theme — 73.5 points — so membership and business quality are pulling in different directions.
One name does a lot of the work here: the top of this list sits 62.7 points clear of its own median, among the widest such gaps of any theme.
10 of 16 land in the model's speculative bucket, among the highest shares of any theme, so this ranking sorts risk as much as it sorts quality.
The Biotech & Gene Editing group at a glance
Where these companies are filed
The 16 members report under 2 different industries, which is exactly why no standard sector view groups them:
Biotechnology15
Drug Manufacturers - Specialty & Generic1
What kind of businesses these are
Average pillar scores across the 16 scored members, against every stock the model scores:
Pillar
Biotech & Gene Editing
Market
Read
Quality
40.9
57.7
16.8 below
Growth
73.7
58.0
15.7 above
Value
31.6
38.4
6.8 below
Pillars run 0–100, and Value is judged against sector peers. A low Value reading means this group is expensive relative to what it earns, not that the businesses are weak.
A few names carry this list. NBIX reaches 87.2 while the median sits down at 24.5, nearer MRNA at 13.7 than the top. A theme is a thesis, not a quality filter — membership says a company is exposed to Biotech & Gene Editing, and the score says what the model makes of the business.
Where analysts are moving on Biotech & Gene Editing
Across the 10 Biotech & Gene Editing names with a reading, the median forward earnings estimate is being cut — -2.5% over 90 days, behind the market (+0.5%). Opinion is close to evenly divided — 4 up, 5 down.
Estimates implied by price ÷ forward P/E, captured together each trading day since June 2026, and outside the Bull Rankings score. 10 of 17 members carry a reading; the rest have no forward P/E to imply one from, which is normal for loss-makers. How this is measured, across the market →
Common questions
What counts as a Biotech & Gene Editing stock?
Commercial biotechs earning real money alongside clinical-stage names whose value rests entirely on a pipeline. The score gap between the two is wide and deliberate — a pre-revenue company is graded on what it has, not on what it might become. The companies are hand-picked by Bartholomew Chupka Jr., the site's founder, from the stocks in our US coverage.
How are the best Biotech & Gene Editing stocks ranked?
Each name is scored on the Bull Rankings quality-growth model — one 0–100 score blending business quality, growth, and valuation — the same score used everywhere on the site.
Are analysts raising or cutting Biotech & Gene Editing earnings estimates?
Across the 10 Biotech & Gene Editing names with a reading, the median forward earnings estimate is being cut — -2.5% over 90 days, behind the market (+0.5%). Opinion is close to evenly divided — 4 up, 5 down. Estimates are implied by price divided by forward P/E, captured together each trading day so only a changed forecast moves the figure, and they sit outside the Bull Rankings score.
How often is the ranking updated?
The universe is re-scored every trading day after the US market close, so the ranking reflects the latest fundamentals and prices.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.